Zydus receives USFDA final approval for Enzalutamide Capsules, 40 mg
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Also received tentative approval for 137 mg
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated